androstane-3-17-diol-glucuronide and allotetrahydrocortisol

androstane-3-17-diol-glucuronide has been researched along with allotetrahydrocortisol* in 1 studies

Other Studies

1 other study(ies) available for androstane-3-17-diol-glucuronide and allotetrahydrocortisol

ArticleYear
Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans.
    The Prostate, 1989, Volume: 14, Issue:1

    The objective of this study was to estimate the minimum in vivo effective oral dose and duration of action of the competitive 5 alpha-reductase inhibitor MK-906, a 4-azasteroid, in humans. Plasma dihydrotesterone (DHT), 5 alpha-androstane-3 alpha,17 beta-diol (AD), and its glucuronide (ADG), as well as urinary androsterone (A) and 5 alpha-pregnane-3 alpha,11 beta, 17 alpha,21-tetrol-20-one (aH4F) were determined in 54 healthy young men before and up to 7 days after a single morning dose of the compound. Twenty-four hours after a single 5- to 40-mg dose (n = 24), plasma DHT levels decreased by a mean of +/- 65%, with slow recovery of DHT levels. Seven days later, DHT remained decreased by +/- 15%. Plasma AD levels decreased to a similar degree, whereas ADG levels decreased by about 75%, indicating inhibition of target tissue 5 alpha-reductase. Testosterone levels did not show any significant variations. The A as well as aH4F excretion in the 24-hour urine test following drug administration decreased by 65%, indicating inhibition of the hepatic 5 alpha-reductase. After a single dose of 1.5 or 0.5 mg, DHT levels decreased by 50% 24 hours after administration, returning to normal within 5-7 days; at this dose, urinary A and aH4F excretion decreased by 50%. A single dose of 0.2 mg appeared to be slightly active as a 5 alpha-reductase inhibitor, but no statistically significant effect on DHT levels was observed after administration of a single 0.04-mg dose. It is concluded that MK-906 is a highly effective 5 alpha-reductase inhibitor in vivo. The effect on plasma DHT lasts for several days after administration of a single oral dose. The data suggest that both hepatic and extrasplanchnic 5 alpha-reductases are inhibited.

    Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Adolescent; Adult; Androgens; Androstane-3,17-diol; Androstenes; Androsterone; Azasteroids; Capsules; Dihydrotestosterone; Drug Evaluation; Finasteride; Humans; Isomerism; Liver; Male; Steroids, Heterocyclic; Testosterone; Tetrahydrocortisol

1989